Clinical Overview: Finerenone for Chronic Kidney Disease Associated With Type 2 Diabetes
May 24th 2022Approved by the FDA in 2021, finerenone is the only non-steroidal mineralocorticoid receptor antagonist that reduces the risk of renal disease progression and cardiovascular events in adults with type 2 diabetes mellitus-mediated chronic kidney disease.
Read More